CA1289475C - Gelatin-encapsulated controlled-release composition - Google Patents

Gelatin-encapsulated controlled-release composition

Info

Publication number
CA1289475C
CA1289475C CA000536084A CA536084A CA1289475C CA 1289475 C CA1289475 C CA 1289475C CA 000536084 A CA000536084 A CA 000536084A CA 536084 A CA536084 A CA 536084A CA 1289475 C CA1289475 C CA 1289475C
Authority
CA
Canada
Prior art keywords
dosage form
unit dosage
pharmaceutical unit
liquid fill
gelatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA000536084A
Other languages
French (fr)
Inventor
Jonathan M. Cohen
Lionel Borkan
Ira R. Berry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Patheon Softgels Inc
Original Assignee
Pharmacaps Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacaps Inc filed Critical Pharmacaps Inc
Application granted granted Critical
Publication of CA1289475C publication Critical patent/CA1289475C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989Microcapsule with solid core [includes liposome]

Abstract

ABSTRACT OF THE INVENTION

A controlled-release pharmaceutical unit dosage form is pro-vided comprising a gelatin capsule enclosing a solid matrix formed by the cation-assisted gelation of a liquid fill incorporating a vegetable gum and a pharmaceutically-active compound, as well as methods for the preparation thereof.

Description

GELATIN-ENCAPSULATED
CONTROLLED-RELEASE
COMPOSITION

Backqround of the Invention Soft gelatin encapsulation of a solution or dis-persion of a pharmaceutical agent in a liquid carrier or a water-soluble gel offers many advantages over other dosage forms such as coated or uncoated compressed solid tablets or bulk liquid preparations. Gelatin encapsulation of a solution or dispersion permits the accurate delivery of a unit dose, an advantage which becomes especially important when relatively small amounts of the active ingredient must be delivered, as in the case of certain hormones. Such accuracy is more difficult to achieve via a tabletting pro-cess wherein solids must be uniformly mixed and compressed, or by incorporation of the total dose of the active ingredient into a bulk liquid carrier which must be measured out prior to each oral administration.
Soft gelatin encapsulation provides a dosage form which is more readily accepted by patients, since the cap-sules are easy to swallow and need not be flavored in order - to mask the unpleasant taste of the active principle. Soft gelatin capsules are also more easily transported by patients than bulk liquids since only the required number of doses need be removed from the package.
Soft gelatin encapsulation further provides the potential to improve the bioavailability of pharmaceutical agents in the gastrointestinal tract. In the case of an oral liquid preparation, a significant amount of the active ingredient may be lost in the mouth or esophageal lining, prior to absorption into the blood. In contrast, with soft gelatin capsuIes, the active ingredients are rapidly released as soon as the gelatin shell ruptures. Complete r~ :
D

, , ~89475 disintegration and dissolution of the capsule are not necessary for the active ingredients to become available for absorption as in the case of tabletted compositions. Also, relatively insoluble active ingredients can be dispersed in a liquid or gelled carrier to provide faster absorption.
For exam le, Miskel et al. (U.S. Pat. No. 3,851,051) dis-closes soft gelatin capsules which contain aqueous solutions or suspensions of active ingredients in a water-soluble gel lattice matrix which is formulated to rapidly disperse upon rupture of the capsule shell. The rapid action of the active ingredient ~s ascribed to the high water content of the simple gel (5-20%) and the absence of an oil vehicle.
The encapsulation of solutions or dispersions of biologically-active compounds in soft gelatin capsules is disclosed in U.S. Pat. Nos. 4,486,412 and 3,784,684.
Formulations intended for the controlled release of pharmaceutically-active compounds ln vivo include solid particles of the active ingredient which are coated or tabletted with film-forming polymers, waxes, fats, silica, and the like. These substances are intended to inhibit the dissolution, dispersion or absorption of the active ingredient in vivo. Although these compositions might be encapsulated in soft gelatin with equipment modifica-tions, the use of such controlled release medicaments can negate many of the advantages associated with the use of liquid filling compositions, such as the ability to uni-formly deliver an accurate dose of the active ingredient.
Therefore, a need exists for controlled-release compositions which are suitable for, and compatible with, soft gelatin encapsulation.
A further need exists for gelatin-encapsulated compositions which can release an accurate dose of a medica-ment therefrom at a controlled rate following rupture of the -.;
-capsule shell. A need also exists for methods for the prep-aration of gelatin-encapsulated, controlled-release com-positions which can uniformly deliver a unit dose of one or more pharmaceutically active compounds in vitro or in vivo.

Brief Description of the Invention The present invention provides a pharmaceutical unit dosage form comprising a gelatin capsule enclosing a water-soluble or dispersible gelled polymeric matrix. The matrix is capable of the controlled release of a pharmaceutically-active compound therefrom at a substan-tially constant rate when the capsule is ruptured in an aqueous medium. The polymeric matrix is not formed by simple coacervation as are the quick-release gels disclosed in the Miskel et al. patent, but rather, i8 formed by the metal or ammonium cation-promoted gelation of a liquid fill, following its encapsulation in the gelatin capsule.
The fill comprises an aqueous solution or dispersion of a polysaccharide gum, such as a colloidal dispersion of a vegetable gum. The gelable fill also includes the active compound and optional amounts of co-solvents, buffers, sur-factants, thickeners and the like.
Thus, the present invention is directed to a pharmaceutical unit dosage form prepared by a process comprising:
~ a) forming a liquid fill comprising an aqueous solution or dispersion of a polysaccharide gum and a pharmaceutically-active compound wherein the solution or dispersion optionally includes an alcohol;
(b) encapsulating said liquid fill in a gelatin capsule; and (c) gelling said liquid fill with an effective amount of a cationic gelling agent.
In a preferred embodiment of the present inven-tion, the cationic gelling agent is incorporated entirely in .

~39475 the gelatin shell, and acts to gel the liquid fill after the fill has been enclosed in the shell. This novel formula-tion method obviates the problems associated with handling fills in which the gelling process is initiated prior to the encapsulation step. The present invention is also directed to the method of forming the control ed-release pharmaceutical unit dosage form.
Therefore, the present dosage form can be used as an ingestible capsule or as a suppository, to accomplish the controlled release of therapeutic agents into physiological media such as gastric fluid, mucus, saliva, vaginal fluid, rectal secretions and the like. The gelled matrix can stabilize the active ingredient and releases the active ingredient at a controlled rate which maintains a uniform level of effective concentrations of the active ingredient.
This controlled release can reduce the side effects due to initial overdosage, prevent wastage of the active ingre-dient and provide better patient compliance.
As employed herein with respect to the active ingredient, the term "controlled release" or "prolonged release" is intended to mean that the present capsules require at least an hour to release a major portion of the active ingredient into the surrounding medium, e.g., about 1-3 hours.
In the following description of the invention, all percentages and parts are by weight unless otherwise noted.

Brief Descri~tion of the Drawin~s Figure 1 is a graphical representation of the rate of release of acetaminophen from a unit dosage form of the invention.
Figure 2 is a graphical representation of the rate of release of niacin from a unit dosage form of the inven-tion.
~';, ;~ ~

, - ,.- , ' , : . .

Detailed Description of the Invention In accord with the present invention, a liquid fill composition i5 prepared by forming an aqueous solution or dispersion of a gelable polysaccharide gum and a pharmaceutically-active compound.

PolYsaccharide Gum ~he polysaccharide gums which are useful to form the polymeric matrices of the invention are selected from those brganic gums which gel or coagulate when solutions or dispersions thereof are contacted with metal or ammonium cations. Preferred gums for use in the present invention include vegetable gums, such as the alkali metal salts of alginic acid ("alginatesn), carrageenan (preferably kappa-carrageenan), pectin, and mixtures thereof. These "strong gumq" re-gel from solution or dispersion to yield a con-tinuous gel structure which is suitable as the polymeric matrix of the invention.
Gellinq Aqent The present gum-containing liquid fills are gelled following their encapsulation by means of an effective amount of one or more cationic gelling agents. These agents comprise alkali metal, alkaline earth metal or ammonium cations. Useful divalent cationic gelling agents also include copper (II), cadmium (II), barium (II), strontium (II), cobalt (II), nickel (II), zinc (II), manganese (II) and iron (II) cations. Useful trivalent cations include aluminum (III), chromium (III) and iron (III). Also useful are heavy metal compounds which yield mobile ions in solu-tion. Preferred water-soluble ionic compounds are selected from pharmaceutically-acceptable fluorides, citrates, phosphates, tartrates, sulfates, acetates, borates, chlo-rides and the like, of cations such as sodium, lithium, B

.

potassium, magnesium, calcium and ammonium. Especially pre-ferred gelling agents include inorganic salts, i.e., chloride salts such as potassium chloride (KCl), calcium chloride (CaCl2) and mixtures thereof.

Solvent The present hydrophillic liquid fills are pre-pared by dispersing or dissolving the gelable gum in an aqueous solvent system which may also include one or more alcoholic co-solvents such as alkanols or glycols.
Therefore, the present solvent systems will contain amounts of water which can act to hydrate the vegeta~le gum or gums which are employed. For a given liquid fill, the amount of water is adjusted so that it does not deleteriously effect the stability of the gelatin capsule wall of the finished prod-uct.
Alcohols which can be employed in the present invention include liquid polyethylene glycols, i.e., polyethylene glycol-200, 300, 400 or 6~0, wherein the suffixed numbers indicate the approximate molecular weight of the glycol. Although a polyethylene glycol can ~e employed as the sole alcoholic solvent for the fill com-ponents, it is often desirable to adjust the viscosity and solubilization power of the primary solvent by the use of co-solvents. Useful co-solvents include other alcohol~, for example:
(a) lower (alkanols), such as ethanol and isopro-panol;
(b) C2 - C4 polyols, such as diol or triol, e.g., propylene glycol, glycerol or mixtures thereof, or (c) derivatives thereof, e.g., propylene car-bonate, lower(alkyl) glycol ethers and the like. In some cases, mixtures of alkanols, polyols or their derivatives ~classes (a)-(c)] can replace the liquid polyethylene glycol component.

B

-,, .
.

~289~75 Pharmaceutically-Active Inqredient The liquid fill can incorporate one or more pharmaceutically-active compounds which will be dispersed or dissolved in the solvent base of the fill in amounts which can S vary widely depending upon the biological activity, the solubility of the active component and the desired rate of release of the active component from the gelled matrix.
Useful classes of pharmaceutically-active compounds which can be delivered by the present dosage forms include analgesics, calcium channel blockers, beta-blockers, antibacterials, antidepressants, antidiabetics, anti-inflammatory agents, cerebral stimulants, sedatives, anti-parasitics, decongestants, muscle relaxants, anti-Parkinsonism ag~nts, bronchodilators, vitamins and dietary supplements such as minerals, fatty acids and the like.

Bulkinq Aqents Bulking agents are optionally included in the fill to adjust the release rate of the pharmaceutical com-pound from the final gelled polymeric matrix. Bulkingagents include, but are not limited to, starches, natural and synthetic cellulosic derivatives such as methyl, ethyl, propyl, hydroxymethyl, hydroxyethyl, hydroxypropyl or hydroxypropylmethylcelluloses, silica and other natural and synthetic silicic acid analogues, other vegetable gums such as iota-carrageenan, lambda-carrageenan, tragacanth, karaya, ghatti, guar, tamarind, psyllium, quince, larch, and the like. Although some of these gums can gel to some extent by coacervation, they do not cation-gel to the degree required to yield a solid matrix which is effective for the controlled release of ~he active ingredient in vivo.

Dispersina Aqents The fill component of the present invention may optionally comprise minor but effective amounts of one or ~' more dispersing agents. The release rate of active ingredients which are insoluble or exhibit low solubility in the aqueous solvent system can be enhanced by the use of the~e dispersants.
Useful dispersants include nonionic surfactants such as the Cl2-C20 fatty acid esters or sorbitol and its anhydrides ("Spans") optionally co-polymerized with about 15-90 moles of ethylene oxide ("Tweens"). Typical polysor-bates which aid in the formation of the present dispersions and can help to stabilize the gelatin capsule include poly-sorbate 20 (a laurate ester); polysorbate 40 (a palmitate ester); polysorbate 60 (a mixture of stearate and palmitate esters); and polysorbate 80 (an oleate ester) wherein the suffixed numbers indicate the approximate mole lS ratio of ethylene oxide to sorbitol. For a general discus-sion of the properties and composition of the polyethylene glycols and the polysorbates, see Remington's Pharmaceutical Sciences, A. Osol, ed., Mack Pub. Co (16th ed. 1980) at pages 1252-1253, the disclosure of which is incorporated by reference herein. Other useful dispersing agents include triglycerides of long or medium chain length such as lecithin and vegetable oils such as palm oil, coconut oil, corn oil, soybean oil and the like. Waxes such as high molecular weight polyethylene glycols (m.w. 1000-8000), beeswax, spermaceti, lanolin, ouricuri, and the like can also function as dispersing agents within the context of the pres-ent invention. The dispersing agents may be present in an amount from about 1-20% by weight of the capsule contents.
Therefore, preferred liquid fill compositions for use as the gel-matrix precursors will comprise about 0.1-20%, preferably about 2-10.0~ o~ the cation-gelable poly-saccharide gum; about 0.05-5%, preferably about 0.1-2.5~ of a cationic gelling agent comprising a metal cation or ammonium ion; and about 0.0001-90%, preferably about 0.1-75~
of a pharmaceutically-active compound. These components are ~ J

, -, , '' ' 128g475 dispersed or dissolved in an aqueous solvent system. Thus, the liquid fill will comprise about 5-75%, preferably about 20-50~ water and optionally, about 5-60%, preferably about 7.5-40% of propylene carbonate or a liquid polyethylene glycol, and about 1-15~ of a C~-C4-polyol, a lower(alkanol) or mixtures thereof. The present liquid fills also can include about 0.1-90%, preferably about 0.3-25%, of a bulking agent such as methyl or ethyl cellulose, a "weak~' vegetable gum, or mixtures thereof, as well as minor but effective amounts of buffers such as citrates, fumarates, adipates and the like.

Enca~sulation The liquid fill can be prepared by adding the gelable gum along with the bulking agent and buffers, if any, to the pre-formed solvent system, with agitation as necessary, followed by addition of one or more active ingre-dients. Although the gelling agent can be incorporated into the liquid fill at this point, it is preferable to incor-porate a part or, most preferably, all of the gelling agentinto the plasticized gelatin which is employed to encap-sulate the fill. Following encapsulation of a suitable amount of the homogenous liquid fill, the gelling agent is brought into contact with the dispersed or dissolved gum and acts to resolidify it to yield a coherent gelled matrix.
The matrix incorporates the active compound uniformly dis-persed throughout.
The capsules are dried to the extent that the residual water in the gelled fill does not deleteriously affect the capsule wall, e.g., until a~out 0.5-12%, prefer-ably about 2.5-7.5% by weight of water is present in the fill.
Although encapsulation of the present fill materials in soft gelatin capsules is preferred, the present method can also be employed to gel fill materials which have ~i 1289-~75 been encapsulated in two-piece hard gelatin capsules or in soft gelatin suppositories, e.g., for the vaginal, rectal, sublingual or buccal administration of the present pharma-ceutical dosage forms. In addition to gelatin, the capsule wall can include water and an effective amount of plasti-cizer such as glycerin, sorbitol or mixtures thereof. The shell of the present capsules can also include minor but effective amounts of opacifiers, coloring agents, preser-vatives and the like.
The invention will be further described by reference to the following detailed examples.

Example I - Acetaminophen Dosaqe Form A. Fill ComPosition Acetaminophen:500 parts Sodium Alginate:15 parts Kappa-Carrageenan:41 parts Iota-Carrageenan:5 parts Water: 468 parts Polyethylene Glycol 400: 468 parts B. Soft Gelatin Shell Gelatin: 199 parts Glycerin: 72 parts Water: 146 parts CaC12: 3 parts KC1: 5 parts C. Fill PreParation The gums, water and polyethylene glycol are combined in a suitable vessel and agitated ~r~
'.;~' until a uniform mixture results. The acetami-nophen is added, and agitation is continued for about 45 min. The liquid blend is then milled.

D. Shell Preparation Gelatin, glycerin and water are added to a suitable vessel and agitated with heat until a uniform melt results. The CaCl2 and the KCl are then added to the molten gelatin.

D. Encapsulation The shel]. preparation was employed to encap-sulate 1200 mg portion of the liquid fill blend employing rotary die encapsulation (#20 oval die) to yield one-piece hermetically-sealed, soft gelatin capsules. Following ~0 encapsulation, the liquid fill gelled to a solid mass which completely filled the interior of the capsule. The gelled polymeric matrix contained 4.3% water.

F. Release Profile StudY
.
:
A USP paddle-type dissolution apparatus was filled with 900 ml of 0.1 N HC1 and four of the acetaminophen capsules were placed in each of the six chambers of the apparatus. The 0.1 N
HCl was stirred at 100 rpm and samples of the test fluid were withdrawn periodically and analyzed spectrophotometrically (A max =
244 nm), employing reference standards to yield the curve depicted in Figure 1. The ::

~ :

: , ~28947~i data summarized in Figure 1 establish that the gelled matrix of the capsule of Example I is effective for the controlled release of aceta-minophen, releasing 50% of the total drug in about 3.0 hrs and 70% after about 7.5 hours.
It is also expected that the dosage form of Example I will be particularly effec-tive for the controlled release of other active ingredients such as ibuprofen, . acetohexamide, tolbutamide, diflunisal, carisoprodol, theophylline, dyphylline, difedipine and digoxin.

ExamPle II - Niacin Dosaqe Form A. ~ill ComPosition Niacin: 1200 parts Sodium Alginate: 120 parts Propylene Glycol: 200 parts Polyethylene Glycol 400:45Q parts Glycerin: 125 parts Ethyl Cellulose: 500 parts Methyl Cellulose: 25 parts .~ ~: Ethanol: 155 parts ; 25 Water: 1,630 parts B. Soft Gelatin Sh_11 Gelatin: 768 parts : : Glycerin: 385 parts Water: 477 parts ,~:
: : C. Salt Solution :~ KCl: :9 parts :: : - CaC12: 16 parts .
~ 35 Water: 85 parts :: . , . :.

~289475 D. Encapsulation The fill and shell formulations are prepared as described for Example I, above, with the exception that the salts were added to the molten gelatin as the solution of part (C).
The shell formulation was employed to encap-sulate 500 mg portions of the milled and deaerated liquid fill via rotary die encap-sulation ~#9, round die) to yield one-piece hermetically-sealed, soft gelatin capsules.
Followin~ encapsulation, the liguid fill gelled to a solid mass. The gelled matrix contained 5.7% water.

E. Release Profile Studv The rate of release of niacin from the cap-sules was determined via the procedures of Example I(F), above, analyzing at a ~ max of 263 nm, to yield to curve depicted in Figure 2. The data summarized in Figure 2 establish that the gelled matrix of the cap-sule o Example II is effective for the con-trolled release of niacin, releasing 60% of the vitamin in about 1.75 hrs and 90% of the vitamin after about 4.S hours.
It is also expected that the dosage form of Example I will be effective for the , controlled release of active ingredients such as codeine, diltiazem, amytriptyline, meclofenemate, ephedrine and phenyl-propanolamine.
Although the present invention has been described primarily in terms of the encapsulation of active ingredients which are intended for administration in humans, the use :
~B

~9475 of the present dosage forms for veterinary, biological or industrial applications is also within the scope of the invention.
While certain representative embodi-ments of the invention have been described herein for purposes of illustration, it will be apparent to those skilled in the art that modifications therein may be made without departing from the spirit and scope of the invention.

: ~ :

J

, : -: :: ~: :: ::

:
~ ~ :

, ` :
~, , :: :

: ` , . -: , ,

Claims (24)

1. A pharmaceutical unit dosage form comprising a gelatin shell enclosing a gelled polymeric matrix, characterized by having been prepared by the process consisting essentially of:
(a) forming a liquid fill comprising an aqueous solution or dispersion of a polysaccharide gum and pharmaceutically-active compound;
(b) encapsulating said liquid fill in a gelatin shell wherein the gelatin shell comprises gelatin, an effective amount of a plasticizer, water and an amount of cationic gelling agent effective to gel said liquid fill; and (c) gelling said liquid fill with the cationic gelling agent.
2. The pharmaceutical unit dosage form of claim 1 wherein the polysaccharide gum is selected from the group consisting of alginate, kappa-carrageenan and pectin.
3. The pharmaceutical unit dosage form of claim 1 wherein the gelling agent comprises a metal cation or an ammonium ion.
4. The pharmaceutical unit dosage form of claim 3 wherein the gelling agent comprises a chloride salt.
5. The pharmaceutical unit dosage form of claim 1 wherein the aqueous solution or dispersion further comprises propylene carbonate or a liquid polyethylene glycol.
6. A method for preparing a controlled-release pharmaceutical unit dosage form comprising:

(a) forming a liquid fill comprising an aqueous solution or dispersion of a polysaccharide gum and a pharmaceutically-active compound;
(b) encapsulating said liquid fill in a gelatin capsule;
and (c) gelling said liquid fill with an effective amount of a cationic gelling agent comprising metal cations or ammonium ions to form a polymeric matrix having said active compound uniformly dispersed throughout.
7. The method of claim 6 wherein the liquid fill is encapsulated in a plasticized gelatin capsule.
8. The method of claim 6 wherein the polysaccharide gum is selected from the group consisting of alginate, kappa-carrageenan, pectin and mixtures thereof.
9. The method of claim 6 wherein the metal cations or the ammonium ions are incorporated in the gelatin capsule.
10. The method of claim 9 wherein the metal cation comprises calcium chloride, potassium chloride or mixtures thereof.
11. A pharmaceutical unit dosage form comprising a gelatin shell including an effective amount of a gelling agent comprising metal cations or ammonium ions, wherein said shell encloses a water-soluble or water-dispersible gelled polymeric matrix and a pharmaceutically-active compound dispersed throughout said matrix, wherein said matrix is formed in situ by the gelation of a liquid fill comprising an aqueous solution or dispersion of the pharmaceutically-active compound and a polysaccharide gum, by means of said gelling agent, following the encapsulation of the liquid fill, so that the pharmaceutically-active compound is released from said gelled polymeric matrix over a prolonged period when said capsule is ruptured in an aqueous medium.
12. The pharmaceutical unit dosage form of claim 11 wherein said gelatin capsule comprises gelatin, an effective amount of a plasticizer, and water.
13. The pharmaceutical unit dosage form of claim 11 wherein said gelatin capsule is a two-piece, hard gelatin capsule.
14. The pharmaceutical unit dosage form of claim 11 wherein said polysaccharide gum comprises a vegetable gum.
15. The pharmaceutical unit dosage form of claim 14 wherein the vegetable gum is selected from the group consisting of alginate, kappa-carrageenan, pectin and mixtures thereof.
16. The pharmaceutical unit dosage form of claim 14 wherein the cationic gelling agent comprises alkali metal cations or alkaline earth metal cations.
17. The pharmaceutical unit dosage form of claim 11 wherein the aqueous solution or dispersion comprises a liquid polyethylene glycol.
18. The pharmaceutical unit dosage form of claim 17 wherein the aqueous solution or dispersion comprises glycerin, propylene glycol or mixtures thereof.
19. The pharmaceutical unit dosage form of claim 17 wherein the aqueous solution comprises a polysorbate or a triglyceride dispersing agent.
20. The pharmaceutical unit dosage form of claim 17 wherein the aqueous solution or dispersion comprises a cellulosic bulking agent.
21. A pharmaceutical unit dosage form comprising a soft gelatin shell including an effective amount of a cationic gelling agent comprising metal cations or ammonium ions, wherein said shell encloses a water-soluble or water-dispersible gelled polymeric matrix and an effective amount of a pharmaceutically-active compound dispersed throughout said matrix, wherein said matrix is formed in situ by the gelation of a liquid fill composition comprising 0.1-20% of a vegetable gum selected from the group consisting of alginate, kappa-carrageenan, pectin and mixtures thereof; the pharmaceutically-active compound, 5-60% of a liquid polyethylene glycol, and 5-75% water; wherein said gelation is accomplished with the cationic gelling agent, following the encapsulation of the liquid fill, so that the pharmaceutically-active compound is released from said gelled polymeric matrix over a prolonged period when said capsule is ruptured in a physiological medium.
22. The pharmaceutical unit dosage form of claim 21 wherein the cationic gelling agent comprises potassium chloride, calcium chloride or mixtures thereof.
23. The pharmaceutical unit dosage form of claim 21 wherein the liquid fill composition further comprises 1-15% of a C2-C4 polyol, a lower (alkanol) or mixtures thereof.
24. The pharmaceutical unit dosage form of claim 21 wherein the liquid fill further comprises 0.1-90% of a bulking agent.
CA000536084A 1986-05-01 1987-04-30 Gelatin-encapsulated controlled-release composition Expired - Lifetime CA1289475C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US858,969 1986-05-01
US06/858,969 US4708834A (en) 1986-05-01 1986-05-01 Preparation of gelatin-encapsulated controlled release composition

Publications (1)

Publication Number Publication Date
CA1289475C true CA1289475C (en) 1991-09-24

Family

ID=25329637

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000536084A Expired - Lifetime CA1289475C (en) 1986-05-01 1987-04-30 Gelatin-encapsulated controlled-release composition

Country Status (6)

Country Link
US (1) US4708834A (en)
EP (1) EP0243930B1 (en)
JP (1) JPS6322032A (en)
AU (1) AU594148B2 (en)
CA (1) CA1289475C (en)
DE (1) DE3775973D1 (en)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3600084A1 (en) * 1986-01-03 1987-07-09 Scherer Gmbh R P MOLDED BODY AND METHOD AND DEVICE FOR PRODUCING SUCH A MOLDED BODY
US4795642A (en) * 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
GB8701332D0 (en) * 1987-01-21 1987-02-25 Lilly Industries Ltd Capsule filling
US5154930A (en) * 1987-03-05 1992-10-13 The Liposome Company, Inc. Pharmacological agent-lipid solution preparation
JPS63218247A (en) * 1987-03-06 1988-09-12 Yoshiaki Kawashima Production of highly functional suspension
US4950689A (en) * 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
US5376381A (en) * 1988-02-25 1994-12-27 The Liposome Company, Inc. Integrity protected gelatin
US5051305A (en) * 1988-12-30 1991-09-24 Arcade, Inc. Stabilized perfume-containing microcapsules and method of preparing the same
US5288479A (en) * 1989-01-17 1994-02-22 Sterling Drug, Inc. Extrudable elastic oral pharmaceutical gel compositions and metered dose dispensers containing them and method of making and method of use thereof
US5001117A (en) * 1989-03-07 1991-03-19 Pharmacaps, Inc. Use of lecithin to restore olfaction and taste
US5035890A (en) * 1989-04-10 1991-07-30 Dow Corning Corporation Emulsifier-free hand and body lotion
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
CA2044878C (en) * 1990-08-07 2000-12-26 Tacey X. Viegas Thermally reversible and irreversible gels
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
JP3313124B2 (en) * 1991-07-31 2002-08-12 森下仁丹株式会社 SEAMLESS CAPSULES CONTAINING A HYDROPHILIC SUBSTANCE AND PROCESS FOR PRODUCING THE SAME
FR2703908B1 (en) * 1993-04-13 1995-06-02 Asta Medica Ag Pharmaceutical form for rectal administration of pharmacologically active compounds.
US5505961A (en) * 1993-08-05 1996-04-09 R. P. Scherer Corporation Gelatin capsules containing a highly concentrated acetaminophen solution
GB2281697A (en) * 1993-09-14 1995-03-15 Euro Celtique Sa Laxative compositions in capsules
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5660859A (en) * 1994-12-29 1997-08-26 Mcneil-Ppc, Inc. Gelling agent for polyethylene glycol
FR2732189B1 (en) * 1995-03-27 1997-05-09 Kodak Pathe ORGANIC-INORGANIC GELS FOR DELIVERING CONTROLLED QUANTITIES OF ACTIVE COMPOUNDS IN AQUEOUS SOLUTIONS
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
US5919481A (en) * 1996-06-28 1999-07-06 Ncneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form
US5908636A (en) * 1996-06-28 1999-06-01 Mcneil-Ppc, Inc. Fill material for soft gelatin pharmaceutical dosage form containing an antiflatulent
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
FR2767070B1 (en) * 1997-08-08 1999-09-17 Laurence Paris AQUEOUS VISCOUS COMPOSITION, LIMPID OR NOT, FOR THE MANUFACTURE OF SOFT CAPSULES AND HARD CAPSULES, AND METHOD FOR MANUFACTURING FILMS FOR SUCH CAPSULES
ES2224642T3 (en) 1998-04-22 2005-03-01 Glycologic Limited ADMINISTRABLE COMPOSITIONS BY ORAL ROUTE, WHICH INCLUDE A POLYACARIDE RETICULATED BY A CARTON AND A DIGERABLE POLYMER IN THE LOWER GASTROINTESTINAL TRACT.
JP3959192B2 (en) * 1998-12-03 2007-08-15 株式会社大塚製薬工場 Tube feeding food
US6159491A (en) * 1999-02-12 2000-12-12 Biovector Technologies, Inc. Prolonged release bioadhesive vaginal gel dosage form
US6383515B2 (en) 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US6365181B1 (en) 2000-04-20 2002-04-02 Gattefosse Corporation Thixatropic gelatin carrier composition
DE10105592A1 (en) 2001-02-06 2002-08-08 Achim Goepferich Placeholder for drug release in the frontal sinus
GB2378693A (en) * 2001-06-16 2003-02-19 Gursharan Moonga Capsules for medicaments, beverages, food colourings and flavours
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US7029698B2 (en) * 2001-11-21 2006-04-18 R.P. Scherer Technologies, Inc. Acetaminophen compositions
US7157493B2 (en) * 2001-11-28 2007-01-02 Nashai Biotech, Llc Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
US20030158265A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising pseudoephedrine hydrochloride and process for preparing the same
US6926906B2 (en) * 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
GB2398005B (en) * 2002-02-20 2005-09-14 Strides Arcolab Ltd Orally administrable pharmaceutical formulation
US20030158264A1 (en) * 2002-02-20 2003-08-21 Ramachandran Radhakrishnan Orally administrable pharmaceutical formulation comprising ephedrine hydrochloride and process for preparing the same
ES2302926T5 (en) * 2002-04-25 2012-08-23 Banner Pharmacaps, Inc. Soft Chewable Capsule
US6890558B2 (en) * 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
ES2355723T3 (en) * 2002-09-11 2011-03-30 Elan Pharma International Limited COMPOSITIONS OF ACTIVE AGENT IN GAN STABILIZED NANOPARTICLES.
US8317816B2 (en) 2002-09-30 2012-11-27 Acclarent, Inc. Balloon catheters and methods for treating paranasal sinuses
US20040146537A1 (en) * 2003-01-28 2004-07-29 Ramachandran Radhakrishnan Oily wax matrix suspension formulation comprising pharmacologically active agents
BRPI0409334A (en) * 2003-04-14 2006-04-25 Fmc Corp heat-resistant, homogeneous gel film, soft capsules, processes for making gel films and soft capsules, and solid form
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
PL2279729T3 (en) * 2003-07-17 2017-02-28 Banner Life Sciences Llc Controlled release preparations
US7462175B2 (en) 2004-04-21 2008-12-09 Acclarent, Inc. Devices, systems and methods for treating disorders of the ear, nose and throat
US20060004323A1 (en) 2004-04-21 2006-01-05 Exploramed Nc1, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US8894614B2 (en) 2004-04-21 2014-11-25 Acclarent, Inc. Devices, systems and methods useable for treating frontal sinusitis
US8764729B2 (en) 2004-04-21 2014-07-01 Acclarent, Inc. Frontal sinus spacer
US9351750B2 (en) 2004-04-21 2016-05-31 Acclarent, Inc. Devices and methods for treating maxillary sinus disease
US7419497B2 (en) 2004-04-21 2008-09-02 Acclarent, Inc. Methods for treating ethmoid disease
US7410480B2 (en) * 2004-04-21 2008-08-12 Acclarent, Inc. Devices and methods for delivering therapeutic substances for the treatment of sinusitis and other disorders
US7720521B2 (en) 2004-04-21 2010-05-18 Acclarent, Inc. Methods and devices for performing procedures within the ear, nose, throat and paranasal sinuses
US9554691B2 (en) 2004-04-21 2017-01-31 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20060063973A1 (en) 2004-04-21 2006-03-23 Acclarent, Inc. Methods and apparatus for treating disorders of the ear, nose and throat
US8864787B2 (en) 2004-04-21 2014-10-21 Acclarent, Inc. Ethmoidotomy system and implantable spacer devices having therapeutic substance delivery capability for treatment of paranasal sinusitis
US7803150B2 (en) 2004-04-21 2010-09-28 Acclarent, Inc. Devices, systems and methods useable for treating sinusitis
US7559925B2 (en) 2006-09-15 2009-07-14 Acclarent Inc. Methods and devices for facilitating visualization in a surgical environment
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
US9089258B2 (en) 2004-04-21 2015-07-28 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US10188413B1 (en) 2004-04-21 2019-01-29 Acclarent, Inc. Deflectable guide catheters and related methods
US7654997B2 (en) 2004-04-21 2010-02-02 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitus and other disorders of the ears, nose and/or throat
US9101384B2 (en) 2004-04-21 2015-08-11 Acclarent, Inc. Devices, systems and methods for diagnosing and treating sinusitis and other disorders of the ears, Nose and/or throat
US8932276B1 (en) 2004-04-21 2015-01-13 Acclarent, Inc. Shapeable guide catheters and related methods
US8702626B1 (en) 2004-04-21 2014-04-22 Acclarent, Inc. Guidewires for performing image guided procedures
US8747389B2 (en) 2004-04-21 2014-06-10 Acclarent, Inc. Systems for treating disorders of the ear, nose and throat
US20070167682A1 (en) 2004-04-21 2007-07-19 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US20070208252A1 (en) 2004-04-21 2007-09-06 Acclarent, Inc. Systems and methods for performing image guided procedures within the ear, nose, throat and paranasal sinuses
US20190314620A1 (en) 2004-04-21 2019-10-17 Acclarent, Inc. Apparatus and methods for dilating and modifying ostia of paranasal sinuses and other intranasal or paranasal structures
US9399121B2 (en) 2004-04-21 2016-07-26 Acclarent, Inc. Systems and methods for transnasal dilation of passageways in the ear, nose or throat
US8146400B2 (en) 2004-04-21 2012-04-03 Acclarent, Inc. Endoscopic methods and devices for transnasal procedures
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8951225B2 (en) 2005-06-10 2015-02-10 Acclarent, Inc. Catheters with non-removable guide members useable for treatment of sinusitis
US8114113B2 (en) 2005-09-23 2012-02-14 Acclarent, Inc. Multi-conduit balloon catheter
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
EP1959935A2 (en) * 2005-10-26 2008-08-27 Banner Pharmacaps Inc. Hydrophilic vehicle-based dual controlled release matrix system as capsule fill
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (en) 2006-04-03 2015-08-12 伊萨·奥迪迪 Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US8190389B2 (en) 2006-05-17 2012-05-29 Acclarent, Inc. Adapter for attaching electromagnetic image guidance components to a medical device
US9820688B2 (en) 2006-09-15 2017-11-21 Acclarent, Inc. Sinus illumination lightwire device
US8439687B1 (en) 2006-12-29 2013-05-14 Acclarent, Inc. Apparatus and method for simulated insertion and positioning of guidewares and other interventional devices
US8118757B2 (en) 2007-04-30 2012-02-21 Acclarent, Inc. Methods and devices for ostium measurement
US8485199B2 (en) 2007-05-08 2013-07-16 Acclarent, Inc. Methods and devices for protecting nasal turbinate during surgery
US8182432B2 (en) 2008-03-10 2012-05-22 Acclarent, Inc. Corewire design and construction for medical devices
JP5676446B2 (en) 2008-07-30 2015-02-25 アクラレント インコーポレイテッド Sinus mouth finder
AU2009293312B2 (en) 2008-09-18 2015-07-09 Acclarent, Inc. Methods and apparatus for treating disorders of the ear nose and throat
US20100241155A1 (en) 2009-03-20 2010-09-23 Acclarent, Inc. Guide system with suction
US7978742B1 (en) 2010-03-24 2011-07-12 Corning Incorporated Methods for operating diode lasers
US8435290B2 (en) 2009-03-31 2013-05-07 Acclarent, Inc. System and method for treatment of non-ventilating middle ear by providing a gas pathway through the nasopharynx
US20110082198A1 (en) * 2009-10-07 2011-04-07 Jiangsu Dehe Bio-Tech Co., Ltd. Theaflavin compositions, production, and methods to control physiological disorders in mammals
US8282970B2 (en) 2009-10-07 2012-10-09 Jiahgsu Dehe Bio-Tech Co., Ltd Theaflavin compositions, related processes and methods of use
US9155492B2 (en) 2010-09-24 2015-10-13 Acclarent, Inc. Sinus illumination lightwire device
US9629684B2 (en) 2013-03-15 2017-04-25 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
CN105307634B (en) 2013-03-15 2020-03-10 沃纳奇尔科特有限责任公司 Pharmaceutical soft gelatin capsule dosage form containing modified guar gum
US9433437B2 (en) 2013-03-15 2016-09-06 Acclarent, Inc. Apparatus and method for treatment of ethmoid sinusitis
CO7200056A1 (en) * 2013-08-27 2015-02-27 Univ Antioquia Ionic gelation on solids
JP6328009B2 (en) * 2014-08-22 2018-05-23 中日本カプセル 株式会社 Soft capsule manufacturing method
ITUB20156821A1 (en) * 2015-12-09 2017-06-09 Altergon Sa JELLY CAPSULES SPRINGS RELEASE INDEPENDENT pH
US20230390210A1 (en) * 2020-10-16 2023-12-07 R.P. Scherer Technologies, Llc Modified release softgel capsules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2963402A (en) * 1955-01-18 1960-12-06 Nysco Lab Inc Sustained release medicament
US3136695A (en) * 1961-03-10 1964-06-09 Strong Cobb Arner Inc Anhydrous thixotropic gel sustained release therapeutic compositions and method of preparation
US3493652A (en) * 1962-09-14 1970-02-03 Charles W Hartman Controlled release medicament
US3228789A (en) * 1962-10-22 1966-01-11 Jacob A Glassman Peroral capsules and tablets and the method for making same
US3361632A (en) * 1964-05-08 1968-01-02 Hoechst Ag Medicinal preparations having a protracted activity and method of making them
US3325472A (en) * 1964-06-18 1967-06-13 Mortimer D Sackler Polycyclohexose-polyoxyethyleneglycol suppository bases
DE1467864A1 (en) * 1964-10-03 1969-01-16 Akad Wissenschaften Ddr Process for the production of spherical shaped bodies from active ingredient-containing aqueous emulsions, suspensions or solutions
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3427378A (en) * 1965-02-12 1969-02-11 American Cyanamid Co Sustained release encapsulated formula
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US3574820A (en) * 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US3558768A (en) * 1969-12-19 1971-01-26 Sterling Drug Inc Sustained release pharmaceutical compositions
US3851051A (en) * 1970-07-17 1974-11-26 Scherer R Corp Soft gelatin capsule containing high water content fill
US3909444A (en) * 1971-08-05 1975-09-30 Ncr Co Microcapsule
GB2009597B (en) * 1977-12-10 1982-06-23 Beecham Group Ltd Antacid compositions
HU179474B (en) * 1978-02-24 1982-10-28 Laszlo Gyarmati Process for preparing solid oral pharmaceutical compositons with increased length of activity and with a regulated release of the active material
US4153677A (en) * 1978-05-18 1979-05-08 Sterling Drug Inc. Controlled-release composition
JPS6042766B2 (en) * 1978-12-09 1985-09-25 日本化薬株式会社 Base
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
US4259315A (en) * 1980-06-13 1981-03-31 A. H. Robins Company, Inc. Controlled release potassium dosage form
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4486412A (en) * 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
AU567155B2 (en) * 1983-04-15 1987-11-12 Damon Biotech Inc. Capsules for releasing core material at constant rate
US4474752A (en) * 1983-05-16 1984-10-02 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
JPS6143108A (en) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd Medicinal drug and its preparation

Also Published As

Publication number Publication date
US4708834A (en) 1987-11-24
EP0243930A1 (en) 1987-11-04
EP0243930B1 (en) 1992-01-15
AU594148B2 (en) 1990-03-01
JPH0579048B2 (en) 1993-11-01
JPS6322032A (en) 1988-01-29
AU7216687A (en) 1987-11-05
DE3775973D1 (en) 1992-02-27

Similar Documents

Publication Publication Date Title
CA1289475C (en) Gelatin-encapsulated controlled-release composition
US4795642A (en) Gelatin-encapsulated controlled-release composition
EP0539059B1 (en) Buoyant controlled release powder formulation
US4814179A (en) Floating sustained release therapeutic compositions
CA1336499C (en) Chewable, edible soft gelatin capsule
EP0713390B1 (en) Gelatin capsules containing a highly concentrated acetaminophen solution
EP0250038B1 (en) Sustained release capsule
CA1073358A (en) Sustained release formulations
US5007790A (en) Sustained-release oral drug dosage form
EP0196700A1 (en) Devices for the controlled release of active substances, as well as process for the preparation thereof
EP0719548B1 (en) Gelling agent for polyethylene glycol
EP0250023B1 (en) Nitrofurantoin dosage form
US20040219186A1 (en) Expandable gastric retention device
US4988679A (en) Liquid sustained release composition
US4814178A (en) Floating sustained release therapeutic compositions
JPH0625064B2 (en) Controlled release potassium chloride
EP0152292A2 (en) Acetaminophen gelatin capsules
EP1416914A1 (en) Expandable gastric retention device
EP0484106A1 (en) Controlled release formulations
EP0547688B1 (en) Sustained release tablets
CA1269043A (en) Floating sustained release therapeutic compositions
EP0475894A1 (en) Gemfibrozil formulations
AU2002225872A1 (en) Expandable gastric retention device

Legal Events

Date Code Title Description
MKLA Lapsed